41 completed, 10 active not recruiting, 8 terminated, 6 recruiting. 33 Phase 3, 24 Phase 2, 10 Not applicable, 1 Phase 1.
Follow ETOP IBCSG Partners Foundation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 Tarlatamab - Extensive Stage Lung Small Cell Cancer | Phase 2 | Recruiting | ETOP IBCSG Partners Foundation | 48 | 2026-04-15 | 2026-09-21 |
| A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy Cemiplimab - Non-Small Cell Lung Cancer | Phase 3 | Recruiting | ETOP IBCSG Partners Foundation | 390 | 2026-01-12 | 2026-10-14 |
| AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC Sotorasib, Lenvatinib - Metastatic Non Small Cell Lung Cancer, KRAS G12C | Phase 2 | Withdrawn | ETOP IBCSG Partners Foundation | 2025-03-01 | 2024-11-20 | |
| A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer. Adjuvant durvalumab - Non Small Cell Lung Cancer | Phase 3 | Recruiting | ETOP IBCSG Partners Foundation | 290 | 2025-01-15 | 2026-05-14 |
| Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer Brigatinib, Durvalumab - NSCLC, Stage III, ALK-rearrangement | Phase 2 | Withdrawn | ETOP IBCSG Partners Foundation | 2024-06-07 | 2024-10-08 | |
| A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer Giredestrant, Triptorelin, Anastrozole - Breast Cancer | Phase 2 | Completed | ETOP IBCSG Partners Foundation | 231 | 2024-01-23 | 2026-02-24 |
| Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC Niraparib - SCLC,Extensive Stage, SLFN11-positive | Phase 2 | Recruiting | ETOP IBCSG Partners Foundation | 44 | 2023-12-20 | 2026-05-29 |
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) Elacestrant, Tamoxifen, Letrozole 2.5mg - ER-positive Breast Cancer, HER2-negative Breast Cancer | Phase 3 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 220 | 2023-12-15 | 2026-10-07 |
| Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status Adagrasib - NSCLC Stage IV, KRAS P.G12C | Phase 2 | Active not recruiting | ETOP IBCSG Partners Foundation | 68 | 2023-06-12 | 2026-09-03 |
| Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI Amivantamab, Lazertinib, Zirabev - Non Small Cell Lung Cancer | Phase 2 | Active not recruiting | ETOP IBCSG Partners Foundation | 60 | 2023-03-27 | 2026-01-21 |
| Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer Stereotactic radiosurgery, Immune checkpoint inhibitor - Non-Small Cell Lung Cancer, Melanoma | Phase 3 | Recruiting | ETOP IBCSG Partners Foundation | 180 | 2022-11-30 | 2026-04-27 |
| Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) Osimertinib, Stereotactic Body Radiation Therapy (SBRT) - NSCLC Stage IV, EGFR Gene Mutation | Phase 2 | Terminated | ETOP IBCSG Partners Foundation | 6 | 2022-08-04 | 2024-06-28 |
| Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET) Trastuzumab, Alpelisib, Fulvestrant - Advanced Breast Cancer | Phase 3 | Terminated | Spanish Breast Cancer Research Group | 27 | 2021-09-14 | 2026-10-15 |
| Sacituzumab Govitecan in Primary HER2-negative Breast Cancer Capecitabine, Carboplatin, Cisplatin - HER2-negative Breast Cancer, Triple Negative Breast Cancer | Phase 3 | Active not recruiting | GBG Forschungs GmbH | 1332 | 2020-10-28 | 2026-04-22 |
| ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma Atezolizumab, Bevacizumab, Carboplatin - EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC | Phase 2 | Completed | ETOP IBCSG Partners Foundation | 95 | 2020-09-29 | 2026-07-29 |
| Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC Durvalumab, Carboplatin, Paclitaxel - Non-small Cell Lung Cancer, Stage IV | Phase 2 | Active not recruiting | ETOP IBCSG Partners Foundation | 96 | 2019-11-19 | 2026-10-05 |
| Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer Palbociclib 125mg, Standard endocrine therapy - Breast Cancer Recurrent | Phase 3 | Active not recruiting | ETOP IBCSG Partners Foundation | 405 | 2019-08-27 | 2026-09-03 |
| Adjuvant Palbociclib in Elderly Patients With Breast Cancer Palbociclib, Docetaxel / cyclophosphamide, doxorubicin/cyclophosphamide - Breast Cancer Stage II, Breast Cancer Stage III | Phase 2 | Active not recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 366 | 2019-06-14 | 2026-05-12 |
| BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma Carboplatin, Pemetrexed, Bevacizumab - Pleural Mesothelioma Malignant Advanced | Phase 3 | Completed | ETOP IBCSG Partners Foundation | 400 | 2019-04-30 | 2026-07-22 |
| To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) Paclitaxel, Trastuzumab, Pertuzumab - Breast Cancer, Estrogen Receptor Positive Tumor | Phase 2 | Completed | ETOP IBCSG Partners Foundation | 147 | 2019-04-16 | 2026-10-21 |
Showing 20 of 69. Sign in to see all of them.
Breast Neoplasms (39) · Carcinoma, Non-Small-Cell Lung (14) · Neoplasm Metastasis (4) · Osteoporosis (4) · Breast Carcinoma In Situ (3) · Carcinoma, Ductal, Breast (2) · Carcinoma, Intraductal, Noninfiltrating (2) · Fatigue (2) · Infertility (2) · Lung Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Breast Neoplasms, Male (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Melanoma (1) · Mesothelioma, Malignant (1)
Tamoxifen (9) · Cyclophosphamide (6) · Letrozole (6) · Triptorelin Pamoate (6) · exemestane (6) · Paclitaxel (5) · Bevacizumab (4) · Carboplatin (4) · Gonadotropin-Releasing Hormone (4) · Radiotherapy (4) · palbociclib (4) · Anastrozole (3) · Capecitabine (3) · Epirubicin (3) · Methotrexate (3)
Switzerland (55) · Italy (46) · Spain (37) · Belgium (31) · France (29) · United Kingdom (23) · Australia (21) · Netherlands (19) · Germany (18) · Ireland (17) · Hungary (14) · Austria (13) · Canada (11) · New Zealand (11) · Sweden (10)
Olivia Pagani, MD (4) · Rolf Stahel, MD (4) · Elisabetta Munzone, MD (3) · Kelly-Anne Phillips (3) · Marco Colleoni, MD (3) · Solange Peters, MD-PhD (3) · Diana Crivellari, MD (2) · Dirk De Ruysscher, MD PhD (2) · Enriqueta Felip, MD-PhD (2) · Guy Jerusalem, MD, PhD (2) · James N. Ingle, MD (2) · Juerg Bernhard, PhD (2) · Martine J. Piccart-Gebhart, MD, PhD (2) · Matthias Guckenberger, MD-PhD (2) · Paul E. Goss, MD, PhD (2)
PMID 24881463, PMID 26092816, PMID 27044936, PMID 28379421, PMID 28911092, PMID 29863451, PMID 31618131, PMID 33853037, PMID 36521078, PMID 40986647, PMID 41637791, PMID 10076722, PMID 10458221, PMID 14551341, PMID 14962527, PMID 16145047, PMID 16157934, PMID 16236737, PMID 16344321, PMID 16382061, PMID 16421418, PMID 16541302, PMID 16730270, PMID 16822845, PMID 17200148, PMID 17208639, PMID 17301074, PMID 17452676, PMID 17492927, PMID 17646669, PMID 17679725, PMID 17912636, PMID 17998546, PMID 18083065, PMID 18279765, PMID 18296421, PMID 18332043, PMID 18332471, PMID 18332474, PMID 18332475, PMID 18364505, PMID 18650162, PMID 18784962, PMID 18981464, PMID 19096768, PMID 19243946, PMID 19364966, PMID 19468030, PMID 19474112, PMID 19528136
2005 (6), 2016 (4), 2018 (4), 2014 (3), 2004 (2), 2017 (2), 2015 (1), U10CA025224 (1), U10CA037429 (1), U10CA077202 (1), U24CA075362 (1)